GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests — 43 comments in the full submission. View in context.
989
c/trialwatch·submitted 17 days ago by u/customs_seizure_sid

[Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests

Paperbranch of 9 comments

Confession thread, sort of. I went from 12.5mg to 5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 23 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have…

Read the full submission and all 43 comments →

This branch

9 comments, started 16 days ago
u/trialwatch_theoMOD85 points·16 days ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/karl_fischer_kev21 points·15 days ago

Mechanistically the bit that matters is TRIUMPH. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/sten_palacios25 points·15 days ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/alcohol_aversion10 points·15 days ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/joaquin_trevino8 points·15 days ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/forest_plot_fionastats4 points·15 days ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/tomas_kimani53 points·15 days ago

Flair changed to match the content.

Adding to this: SURMOUNT is doing more work than the comment implies.

replysharereportpermalink
u/yara_bakken28 points·15 days ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/week_four_wall9 points·15 days ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →